Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2016 (2016), Article ID 8298503, 14 pages
http://dx.doi.org/10.1155/2016/8298503
Clinical Study

Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson’s Disease

1Lighthouse Guild, Arlene R. Gordon Research Institute, New York, NY, USA
2Department of Ophthalmology, NYU School of Medicine, New York, NY, USA
3Institute of Vision, Aging in Vision and Action Lab, CNRS-INSERM, University Pierre & Marie Curie, Paris, France
4Jesse Brown VA Medical Center, Chicago, IL, USA
5Institute for Neurodegenerative Disorders, Suite 8B, 60 Temple Street, New Haven, CT 06510, USA
6New York Eye & Ear Infirmary and Icahn School of Medicine of Mount Sinai, 310 East 14th Street, New York, NY 10003, USA
7Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA

Received 1 July 2016; Revised 6 October 2016; Accepted 31 October 2016

Academic Editor: Hélio Teive

Copyright © 2016 William Seiple et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. K. Archibald, M. P. Clarke, U. P. Mosimann, and D. J. Burn, “The retina in Parkinsons disease,” Brain, vol. 132, no. 5, pp. 1128–1145, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. R. A. Armstrong, “Visual symptoms in Parkinson's disease,” Parkinson's Disease, vol. 2011, Article ID 908306, 9 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Nguyen-Legros, “Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease,” Surgical and Radiologic Anatomy, vol. 10, no. 2, pp. 137–144, 1988. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Harnois and T. Di Paolo, “Decreased dopamine in the retinas of patients with Parkinson's disease,” Investigative Ophthalmology and Visual Science, vol. 31, no. 11, pp. 2473–2475, 1990. View at Google Scholar · View at Scopus
  5. R. Inzelberg, J. A. Ramirez, P. Nisipeanu, and A. Ophir, “Retinal nerve fiber layer thinning in Parkinson disease,” Vision Research, vol. 44, no. 24, pp. 2793–2797, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. J. M. Miyasaki, W. Martin, O. Suchowersky, W. J. Weiner, and A. E. Lang, “Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology,” Neurology, vol. 58, no. 1, pp. 11–17, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Pahwa, S. A. Factor, K. E. Lyons et al., “Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology,” Neurology, vol. 66, no. 7, pp. 983–995, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. J. J. Ferreira, R. Katzenschlager, B. R. Bloem et al., “Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease,” European Journal of Neurology, vol. 20, no. 1, pp. 5–15, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. Boehringer Ingelheim Pharmaceuticals Inc. Mirapex (pramipexole dihydrochloride) prescribing information, 2016, http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Mirapex/Mirapex.pdf.
  10. GlaxoSmithKline, REQUIP® (ropinirole tablets) prescribing information, 2014, https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Requip/pdf/REQUIP-PI-PIL.PDF.
  11. UCB Inc. Neupro (Rotigotine Transdermal System) prescribing information, 2007, http://www.neupro.com/pdf/Neupro-PI.pdf.
  12. P. Hardus, W. M. Verduin, M. Engelsman et al., “Visual field loss associated with vigabatrin: quantification and relation to dosage,” Epilepsia, vol. 42, no. 2, pp. 262–267, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Van der Torren, H. S. Graniewski-Wijnands, and B. C. P. Polak, “Visual field and electrophysiological abnormalities due to vigabatrin,” Documenta Ophthalmologica, vol. 104, no. 2, pp. 181–188, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. C. G. Goetz, W. Poewe, O. Rascol et al., “Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations,” Movement Disorders, vol. 19, no. 9, pp. 1020–1028, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Fahn and R. Elton, “Members of the UPDRS development committee,” in Recent Developments in Parkinson's Disease, S. Fahn, C. D. Marsden, D. B. Calne, and M. Goldstein, Eds., vol. 2, pp. 293–304, Macmillan Health Care Information, Florham Park, NJ, USA, 1987. View at Google Scholar
  16. N. S. Gittings and J. L. Fozard, “Age related changes in visual acuity,” Experimental Gerontology, vol. 21, no. 4-5, pp. 423–433, 1986. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Erb, M. Adler, N. Stübiger, M. Wohlrab, E. Zrenner, and H.-J. Thiel, “Colour vision in normal subjects tested by the colour arrangement test ‘Roth 28-hue desaturated’,” Vision Research, vol. 38, no. 21, pp. 3467–3471, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. W. Seiple, T. S. Vajaranant, J. P. Szlyk et al., “Multifocal electroretinography as a function of age: the importance of normative values for older adults,” Investigative Ophthalmology & Visual Science, vol. 44, no. 4, pp. 1783–1792, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Stemplewitz, M. Keserü, D. Bittersohl et al., “Scanning laser polarimetry and spectral domain optical coherence tomography for the detection of retinal changes in Parkinson's disease,” Acta Ophthalmologica, vol. 93, no. 8, pp. e672–e677, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Bittersohl, B. Stemplewitz, M. Keserü, C. Buhmann, G. Richard, and A. Hassenstein, “Detection of retinal changes in idiopathic Parkinson's disease using high-resolution optical coherence tomography and heidelberg retina tomography,” Acta Ophthalmologica, vol. 93, no. 7, pp. e578–e584, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Garcia-Martin, M. Satue, S. Otin et al., “Retina measurements for diagnosis of Parkinson disease,” Retina, vol. 34, no. 5, pp. 971–980, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. J. C. Steele, R. Wresch, S. D. Hanlon, J. Keystone, and Y. Ben-Shlomo, “A unique retinal epitheliopathy is associated with amyotrophic lateral sclerosis/Parkinsonism-Dementia complex of Guam,” Movement Disorders, vol. 30, no. 9, pp. 1271–1275, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Yin, Z.-M. Tian, S. Liu et al., “Transplantation of human retinal pigment epithelium cells in the treatment for Parkinson disease,” CNS Neuroscience and Therapeutics, vol. 18, no. 12, pp. 1012–1020, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Patil, A. Saha, E. Senda et al., “Selective impairment of a subset of Ran-GTP-binding domains of Ran-binding protein 2 (Ranbp2) suffices to recapitulate the degeneration of the retinal pigment epithelium (RPE) triggered by Ranbp2 ablation,” The Journal of Biological Chemistry, vol. 289, no. 43, pp. 29767–29789, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. Ó. M. Björnsson, P. Syrdalen, A. C. Bird, T. Peto, and B. Kinge, “The prevalence of age-related maculopathy (ARM) in an urban Norwegian population: The Oslo Macular Study,” Acta Ophthalmologica Scandinavica, vol. 84, no. 5, pp. 636–641, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Jonasson, A. Arnarsson, H. Sasaki, T. Peto, K. Sasaki, and A. C. Bird, “The prevalence of age-related maculopathy in Iceland: reykjavik eye study,” Archives of Ophthalmology, vol. 121, no. 3, pp. 379–385, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Krishnan, R. D. Ravindran, G. V. S. Murthy et al., “Prevalence of early and late age-related macular degeneration in India: the INDEYE study,” Investigative Ophthalmology and Visual Science, vol. 51, no. 2, pp. 701–707, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Silvestri, M. A. Williams, C. McAuley et al., “Drusen prevalence and pigmentary changes in Caucasians aged 18–54 years,” Eye, vol. 26, no. 10, pp. 1357–1362, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. M. J. Jaffe, G. Bruno, G. Campbell, R. A. Lavine, C. N. Karson, and D. R. Weinberger, “Ganzfeld electroretinographic findings in parkinsonism: untreated patients and the effect of levodopa intravenous infusion,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 50, no. 7, pp. 847–852, 1987. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Schneider and E. Zrenner, “The effect of fluphenazine on rod-mediated retinal responses,” Documenta Ophthalmologica, vol. 65, no. 3, pp. 287–296, 1987. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Li and J. E. Dowling, “Effects of dopamine depletion on visual sensitivity of zebrafish,” Journal of Neuroscience, vol. 20, no. 5, pp. 1893–1903, 2000. View at Google Scholar · View at Scopus
  32. R. Klein, B. E. K. Klein, K. L. P. Linton, and D. L. De Mets, “The Beaver Dam Eye Study: visual acuity,” Ophthalmology, vol. 98, no. 8, pp. 1310–1315, 1991. View at Publisher · View at Google Scholar · View at Scopus
  33. D. G. Birch and J. L. Anderson, “Standardized full-field electroretinography: normal values and their variation with age,” Archives of Ophthalmology, vol. 110, no. 11, pp. 1571–1576, 1992. View at Publisher · View at Google Scholar · View at Scopus
  34. G. J. Jaffe, J. A. Alvarado, and R. P. Juster, “Age-related changes of the normal visual field,” Archives of Ophthalmology, vol. 104, no. 7, pp. 1021–1025, 1986. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Brusini, “Ageing and visual field data,” British Journal of Ophthalmology, vol. 91, no. 10, pp. 1257–1258, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. P. G. D. Spry and C. A. Johnson, “Senescent changes of the normal visual field: an age-old problem,” Optometry and Vision Science, vol. 78, no. 6, pp. 436–441, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Rudolph and L. Frisén, “Influence of ageing on visual field defects due to stable lesions,” British Journal of Ophthalmology, vol. 91, no. 10, pp. 1276–1278, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Müller, W. Kuhn, T. Büttner, and H. Przuntek, “Distorted colour discrimination in Parkinson's disease is related to severity of the disease,” Acta Neurologica Scandinavica, vol. 96, no. 5, pp. 293–296, 1997. View at Google Scholar · View at Scopus
  39. M. J. Price, R. G. Feldman, D. Adelberg, and H. Kayne, “Abnormalities in color vision and contrast sensitivity in Parkinson’s disease,” Neurology, vol. 42, no. 4, pp. 887–890, 1992. View at Publisher · View at Google Scholar · View at Scopus
  40. O. Veselá, E. Růžička, R. Jech et al., “Colour discrimination impairment is not a reliable early marker of Parkinson's disease,” Journal of Neurology, vol. 248, no. 11, pp. 975–978, 2001. View at Publisher · View at Google Scholar · View at Scopus